OPHTHALIX INC COM USD0.001(POST REV SPLIT (OPLI)

1.00
0.55 122.22
OTC
Prev Close 0.45
Open 1.00
Day Low/High 1.00 / 1.00
52 Wk Low/High 0.36 / 1.01
Volume 500.00
Exchange OTC
Shares Outstanding 10.44B
Market Cap 10.44M
Div & Yield N.A. (N.A)

Can-Fite's CF101 Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma

- CF101's Phase II glaucoma trial recently completed enrollment- Glaucoma market is estimated to reach $3 billion by 2023

Can-Fite Subsidiary, OphthaliX, Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101

CF101 is one of only a few oral drugs being developed for the glaucoma market estimated to be $3 billion in 2023

OphthaliX Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101

CF101 is one of only a few oral drugs being developed for the glaucoma market estimated to be $3 billion in 2023

OphthaliX Launches Updated Website To Reflect Proposed Acquisition Of I.V.S.

Pending acquisition to add medical devices in development serving multi-billion dollar markets to Company's drug development portfolio

Can-Fite Subsidiary OphthaliX Signs Definitive Agreement To Acquire Improved Vision Systems Ltd.

Strategic acquisition to combine medical devices and pharmaceutical products to address multi-billion dollar markets in treating ophthalmic diseases

OphthaliX Signs Definitive Agreement To Acquire Improved Vision Systems Ltd.

Strategic acquisition to combine medical devices and pharmaceutical products to address multi-billion dollar markets in treating ophthalmic diseases

Can-Fite Subsidiary, OphthaliX, Signs Term Sheet To Acquire Improved Vision Systems Ltd.

New OphthaliX strategy aims to combine ophthalmic medical devices and pharmaceutical products to address multi-billion dollar markets in treating ophthalmic diseases

OphthaliX Signs Term Sheet To Acquire Improved Vision Systems Ltd.

New strategy aims to combine ophthalmic medical devices and pharmaceutical products to address multi-billion dollar markets in treating ophthalmic diseases

Second Part Of The Glaucoma Phase II Study Has Been Approved In A European Country

CF101 is currently one of the few Oral Drugs developed for Glaucoma

OphthaliX Provides An Update On Its Clinical Developments And Strategic Plans

-Glaucoma Phase II ongoing study will enroll patients to the next higher dose without an interim analysis, no safety issues have been recorded

Can-Fite Granted Patent On The Manufacturing Of CF101 In Japan

The patent confers exclusive right for the manufacturing of CF101 in Japan until 2028 and bolsters license agreement that Can-Fite has already signed in Japan

Can-Fite Comments On Global Rheumatoid Arthritis Market Opportunity

Company's Proprietary Drug CF101 Well-Positioned to Benefit from a Global RA Drug Market Study Forecasted to Generate Revenues of $38.5 bn in 2017

Can-Fite To Present At Two Upcoming Healthcare Investor Conferences

OneMedForum San Francisco 2014 on January 13th

OphthaliX To Retrospectively Analyze Phase III Dry Eye Syndrome Study Data Based On A3 Adenosine Receptor Biomarker

Following the Successful Utilization of A3 Adenosine Receptor Biomarker in Can-Fite's Phase IIb Rheumatoid Arthritis Study